4 results
To evaluate the efficacy of AD 923 in comparison to MSIR in the management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids.
To obtain more information about the efficacy and tolerability of AD 923 in long-term management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids and receive therapy for BTP.
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
The purpose of this clinical trial is to demonstrate the efficacy and safety of the Rheos system in subjects with JNC-7 defined stage II hypertension that is resistant to treatment with at least three anti-hypertension agents, one of which is a…